Refine
Year of publication
Document Type
- Article (5330)
- Doctoral Thesis (1508)
- Part of Periodical (211)
- Conference Proceeding (189)
- Preprint (171)
- Book (86)
- Contribution to a Periodical (67)
- Review (50)
- Working Paper (22)
- Part of a Book (17)
Language
Keywords
- inflammation (80)
- COVID-19 (60)
- SARS-CoV-2 (48)
- Inflammation (38)
- apoptosis (38)
- cancer (38)
- glioblastoma (38)
- breast cancer (34)
- autophagy (29)
- prostate cancer (28)
Institute
- Medizin (7671) (remove)
Einleitung: Empathie ist ein entscheidender Faktor mit direktem Bezug auf das therapeutische Outcome in der Arzt-Patienten Beziehung. Die Ausbildung junger Mediziner:innen ist jedoch sehr fachlich orientiert, soziale Fähigkeiten werden nur in geringem Ausmaß gelehrt. Am Fachbereich Medizin der Goethe Universität Frankfurt wurden Simulationspatient:innen (SPs) bisher hauptsächlich in Prüfungen eingesetzt, nicht aber in der Lehre. Die vorliegende Arbeit beschäftigt sich mit der Fragestellung, ob der Einsatz von SPs in der curricularen Lehre im Fach Chirurgie zur Vermittlung von strukturierten chirurgischen Anamnese- und Aufklärungsgesprächen umsetzbar ist, ob dieses einen Einfluss auf das empathische Verhalten der Studierenden hat, und ob es bei der gezeigten Empathie einen Unterschied zwischen SPs und reale Patient:innen (RPs) gibt. Zusätzlich wird untersucht, ob der Einsatz von SPs einen Einfluss auf den Lernerfolg in kommunikationsbasierten Prüfungen hat.
Methoden: Studienteilnehmende waren Studierende im 3. klinischen Semester am Fachbereich Medizin der Goethe Universität, die aktuell ihr curriculares Blockpraktikum Chirurgie absolvierten. Im Rahmen des Blockpraktikums Chirurgie durchliefen die Studierenden das ‚Training Praktischer Fertigkeiten‘ und hierbei das Modul ‚Kommunikation (Anamnese und Aufklärung)‘. Das Modul dauerte insgesamt 210 Minuten und setzte sich aus theoretischen Einheiten sowie praktischen Übungen (Rollenspielen) zusammen. Die Studienteilnehmenden wurden in 3 Studiengruppen randomisiert. Alle Teilnehmenden füllten zunächst zwei Fragebögen zum selbsteingeschätzten Empathielevel aus und lernten die identischen theoretischen Inhalte des Moduls. In den Rollenspielen trainierte Gruppe 1 mit SPs und wusste auch, dass es sich um SPs handelt. Gruppe 2 übte ebenfalls mit SPs, ging aber davon aus, dass es sich um reale Patient:innen handelte (Inkognito Patient:innen = IPs), Gruppe 3 übte mit RPs und war auch darüber informiert. Im Anschluss wurden die Studierenden anhand eines 10-Items Fragebogen in Hinblick auf die gezeigte Empathie durch die (Simulations-)-Patient:innen bewertet. Der Lernerfolg wurde anhand der Ergebnisse des Chirurgie-OSCE’s, den die Teilnehmenden 5-12 Wochen nach dem Modul absolvierten, ausgewertet.
Ergebnisse: Es zeigten sich signifikante Unterschiede bei dem vom Patienten wahrgenommenen Empathielevel zwischen Gruppe 1 (SP) und 2 (IP) und 1 (SP) und 3 (RP), nicht aber zwischen Gruppe 2 (IP) und 3 (RP). In dieser Konstellation wurden Studierende, welche mit RPs übten oder zumindest davon ausgingen, signifikant weniger empathisch bewertet. Es zeigten sich signifikante Unterschiede in der Eigeneinschätzung zwischen Männern und Frauen, nicht aber in der Fremdeinschätzung. Es gab keine signifikanten Unterschiede in den Ergebnissen der kommunikationsbasierenden Stationen der Chirurgie-OSCE zwischen den einzelnen Gruppen.
Schlussfolgerung: Der Einsatz von SPs im Hinblick auf den Lernerfolg in kommunikationsbasierenden Prüfungen ist gerechtfertigt und eine gute Möglichkeit, um Studierenden das Üben von Gesprächssituationen realistisch zu ermöglichen, ohne dabei akut klinische Patient:innen rekrutieren zu müssen. Dabei muss aber beachtet werden, dass das empathische Verhalten der Studierenden ein anderes ist, wenn sie mit RPs arbeiten, beziehungsweise davon ausgehen, mit einem RP zu arbeiten. Zur Förderung der Empathie sollten RPs und Feedback durch diese früh in die studentische Lehre implementiert werden.
The postthrombotic syndrome (PTS) is beside the venous thromboembolism (VTE) recurrence and chronic thromboembolic pulmonary hypertension (CTEPH) a long-term adverse outcome and chronic complication of deep vein thrombosis (DVT) in the lower extremities and can occur in up to 20–50% of patients within 2 years after DVT. The prevalence of PTS in the adult population is expected to increase due to the growing incidence of VTE in the elderly. Although not life threatening it can impose significant morbidity and can be associated with a negative impact on quality of life associated with disease severity. From an economic point of view, PTS is an important predictor of increased health care costs after VTE.
Factors potentially related to the development of the PTS are older age, obesity, a history of previous ipsilateral DVT, iliofemoral location of the current thrombosis, failure to promptly recover from the acute symptoms and insufficient quality of oral anticoagulant therapy. Furthermore, it is known that the severity of PTS correlates with the location of the DVT, the more proximal the more severe.
PTS induces a range of symptoms and clinical signs, which can be assessed in different scales. The Villalta scale is one of the most suitable scales for defining the presence and severity of subjective symptoms and physical signs of PTS.
In the last century, various therapeutic strategies have been developed to prevent mortality due to VTE or long-term morbidity due to PTS.
Conservative treatment today consists of anticoagulation - usually using direct oral anticoagulants - and compression therapy. One of the first invasive treatments with the aim of thrombus removal was surgical venous thrombectomy by Läwen in 1938. Mahorner and Fontaine improved the technique in the 1950s combining it with a course of anticoagulant treatment to prevent rethrombosis and PTS.
Mechanical thrombectomy by the use of Fogarty balloons, which started in 1963, or the creation of a transient arteriovenous fistula, performed since 1974, are now no longer recommended due to the high invasiveness, risk of fatal intraoperative embolism and a high rethrombosis rate.
In current practice, early thrombus removal mainly relies on the use of catheter-directed pharmacologic thrombolytic therapy. Another approach currently is the endovenous, device-driven thrombectomy and stenting in case of venous obstruction. There is an ongoing broad discussion as to whether these invasive therapies should be offered to patients with iliofemoral thrombosis (IFT), which remains controversial.
IFT, the major target for endovenous thrombectomy respectively pharmacologic thrombolytic therapy, is not enough represented in current literature because the used definition of proximal DVT does not necessarily include the iliac veins. In consequence, it may not be representative enough concerning questions like prevalence and severity of PTS or the effects on quality of life.
The present registry – the Iliaca-PTS registry – addresses exactly these patients and tries to answer these questions. The data of 85 patients who had suffered an IFT in the past were evaluated in the prospective registry documenting the severity of PTS, the occurrence of iliac vein compression syndrome in left-sided IFT and quality of life. A significant predictor for the development of severe PTS or venous claudication in our patient population is a high BMI.
The results of this registry show that IFT is frequently observed and only ten percent develop a moderate or severe PTS respectively venous claudication. In conclusion, the conservative treatment strategy with optimal effective anticoagulant therapy can lead to a low incidence of PTS and a high quality of life.
Background: Decedents who are repatriated to Germany from abroad are not systematically registered nationwide. In Hamburg, in addition to an epidemic hygienic examination, registration and examination of the content of the documents accompanying the corpses of German citizens has been carried out since 2007. In this way, unclear and non-natural deaths in particular are to be followed up as necessary.
Material and methods: Protocols of external and internal autopsies of German nationals who died abroad and were repatriated to Hamburg via the port or airport between 2007 and 2018 were retrospectively evaluated with respect to numbers, completeness of the autopsy abroad and correctness of manner and cause of death.
Results: Between 2007 and 2018 a total of 703 corpses were repatriated via the port or airport of Hamburg and examined by the Port Medical Service for epidemic hygiene and for anything conspicuous in the documents accompanying the corpse. Of them, 307 corpses were examined at the Institute of Legal Medicine at the University Medical Center Hamburg-Eppendorf. In total, 82.4% of the examined cases had an incorrect, unspecific or incomplete foreign death certificate. Of the deceased, 238 were subjected to a second external autopsy by a forensic pathologist and 69 deceased were autopsied again or for the first time in Hamburg. It was found that 84% of the autopsies performed abroad were not performed according to German and European standards. The most common discrepancy was incomplete preparation of the organs. In almost one quarter of the autopsies performed in Hamburg a different cause of death than abroad was determined at autopsy.
Conclusion: Since the quality of autopsies performed abroad sometimes does not meet the standards in Germany and Europe and many papers accompanying corpses are incomplete or incorrectly filled out, a systematic review procedure in the home country is recommended. Through the system established in Hamburg in 2007, at least a re-evaluation of the cases takes place.
Background: In a phase 3 clinical study, patients from Germany with moderate to severe psoriasis who were naïve to systemic treatment and received risankizumab had greater and more rapid disease improvements compared with those who received fumaric acid esters (FAEs).
Objective: To evaluate patient-reported outcomes (PROs) in patients treated with risankizumab compared with FAEs.
Methods: Adult patients were randomized 1:1 to receive either risankizumab 150 mg subcutaneous injections at weeks 0, 4 and 16 or FAEs (Fumaderm®) provided according to the prescribing label. PRO secondary endpoints assessed were Psoriasis Symptom Scale (PSS), Dermatology Life Quality Index (DLQI), 36-Item Short Form Health Survey, version 2 (SF-36v2), Patient Benefit Index (PBI), Hospital Anxiety and Depression Scale (HADS), Patient Global Assessment (PtGA) and European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L). PROs were assessed at weeks 0, 16 and 24.
Results: Sixty patients each were randomized to receive risankizumab or FAEs. A significant PSS improvement was observed with risankizumab vs. FAEs at weeks 16 and 24 for total and psoriasis-associated redness, itching and burning scores (P < 0.001). DLQI scores were significantly lower (reflecting better health-related quality of life) with risankizumab vs. FAEs, with least squares (LS) mean differences of −7.4 and −7.6 at weeks 16 and 24, respectively (both P < 0.001). Patients randomized to risankizumab also had larger improvements in SF-36 Physical and Mental Component Summary scores, HADS anxiety and depression scores, PtGA, and EQ-5D-5L index and visual analogue scale scores (all P ≤ 0.002) at weeks 16 and 24 compared with FAEs. PBI was significantly higher, indicating greater benefit, with risankizumab vs. FAEs, with an LS mean difference of 1.1 and 1.3 at weeks 16 and 24, respectively (both P < 0.001).
Conclusions: Risankizumab provides significant benefits over FAEs in improving PROs across several dimensions in patients with moderate to severe psoriasis.
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial
(2021)
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for most children with juvenile myelomonocytic leukemia (JMML). Novel therapies controlling the disorder prior to HSCT are needed. We conducted a phase 2, multicenter, open-label study to evaluate the safety and antileukemic activity of azacitidine monotherapy prior to HSCT in newly diagnosed JMML patients. Eighteen patients enrolled from September 2015 to November 2017 were treated with azacitidine (75 mg/m2) administered IV once daily on days 1 to 7 of a 28-day cycle. The primary end point was the number of patients with clinical complete remission (cCR) or clinical partial remission (cPR) after 3 cycles of therapy. Pharmacokinetics, genome-wide DNA-methylation levels, and variant allele frequencies of leukemia-specific index mutations were also analyzed. Sixteen patients completed 3 cycles and 5 patients completed 6 cycles. After 3 cycles, 11 patients (61%) were in cPR and 7 (39%) had progressive disease. Six of 16 patients (38%) who needed platelet transfusions were transfusion-free after 3 cycles. All 7 patients with intermediate- or low-methylation signatures in genome-wide DNA-methylation studies achieved cPR. Seventeen patients received HSCT; 14 (82%) were leukemia-free at a median follow-up of 23.8 months (range, 7.0-39.3 months) after HSCT. Azacitidine was well tolerated and plasma concentration-–time profiles were similar to observed profiles in adults. In conclusion, azacitidine monotherapy is a suitable option for children with newly diagnosed JMML. Although long-term safety and efficacy remain to be fully elucidated in this population, these data demonstrate that azacitidine provides valuable clinical benefit to JMML patients prior to HSCT. This trial was registered at www.clinicaltrials.gov as #NCT02447666.
Lippen-Kiefer-Gaumenspalten sind häufige, angeborene Fehlbildungen beim Menschen und werden zumeist schon innerhalb des ersten Lebensjahres operativ korrigiert. In 5-11% der Fälle ist das Vorliegen einer solchen Anomalie mit einer schwierigen Laryngoskopie assoziiert und kann ein modifiziertes Vorgehen bei der Sicherung des Atemweges erfordern. Videolaryngoskopische Techniken kommen hierbei vermehrt zum Einsatz und können auch im Kindesalter zu einer Verbesserung der Intubationsbedingungen beitragen.
In der vorliegenden Arbeit wurden die Intubationsbedingungen zwischen der indirekten Laryngoskopie mittels Glidescope® GVL Spatel Gr. 2 und der indirekten sowie direkten Laryngoskopie mittels C-MAC® Miller-Spatel Gr. 1 bei Kindern mit Lippen-Kiefer-Gaumenspalte miteinander verglichen.
Über einen Zeitraum von acht Monaten wurden Kinder mit Lippen-Kiefer-Gaumenspalte prospektiv abwechselnd entweder indirekt mit dem Glidescope® oder direkt und indirekt mit dem C-MAC® laryngoskopiert. Die Visualisierung der Glottisebene nach der modifizierten Cormack und Lehane Klassifikation war das Hauptzielkriterium. Sekundäre Zielparameter waren unter anderem die Zeit bis zur optimalen Sicht und die Zeit bis zur Intubation.
36 Kinder, die sich einer elektiven Korrektur einer Lippen-Kiefer-Gaumenspalte unterzogen, wurden eingeschlossen und erfolgreich intubiert. Jeweils 18 Kinder wurden mit dem C-MAC® Miller-Spatel Gr. 1 und mit dem Glidescope® GVL-Spatel Gr. 2 laryngoskopiert. Im Vergleich zwischen direkter und indirekter Laryngoskopie mit dem C-MAC® zeigte sich bei vier (22%) Kindern eine deutliche Verbesserung der Visualisierung der Glottisebene von einer schlechten Visualisierung (CL2b, 3 und 4) hin zu einer guten Visualisierung (CL2a und 1) der Glottisebene. Bei Verwendung des Glidescope® lag lediglich in einem Fall eine schlechte Visualisierung der Glottisebene vor.
Der Einsatz indirekter videolaryngoskopischer Techniken kann die Visualisierung der Glottisebene verbessern und reduziert die Anzahl an schwierigen Laryngoskopien bei Kindern mit Lippen-Kiefer-Gaumenspalte.
Hintergrund und Ziel der Arbeit: Aufgrund des demografischen Wandels ist mit einer Änderung des Altersspektrums bei den Obduktionen zu rechnen. Ziel der Arbeit war die Untersuchung der nichtnatürlichen Todesfälle, bei denen die Verstorbenen ein Mindestalter von 65 Jahren erreicht hatten, da dieser Populationsgruppe zukünftig eine wachsende Bedeutung zukommen wird. Material und Methoden: In dieser retrospektiven Mortalitätsstudie wurden alle nichtnatürlichen Todesfälle mit einem Sterbealter ≥ 65 Jahren analysiert, die in den Jahren 2000–2002 (Zeitraum I) und 2013–2015 (Zeitraum II) im Institut für Rechtsmedizin des Universitätsklinikums der Goethe-Universität in Frankfurt am Main obduziert wurden. Für die Analyse der suizidal Verstorbenen wurden zudem Daten nichtobduzierter Selbsttötungen (n = 100) aus Besichtigungen aufgenommen. Ergebnisse: Aus den 1206 Obduktionen resultierten 669 natürliche (55,5 %) und 404 nichtnatürliche (33,5 %) Todesfälle. Darunter ergaben sich 221 Unfälle (Zeitraum I n = 105; Zeitraum II n = 116), 82 Suizide (Zeitraum I n = 55; Zeitraum II n = 27), 41 Todesfälle im Zusammenhang mit medizinischen Interventionen (Zeitraum I n = 7; Zeitraum II n = 34) und 40 Tötungsdelikte (Zeitraum I n = 23; Zeitraum II n = 17). Verkehrsunfälle und Stürze bilden die größten Subgruppen bei den Unfällen. Erhängen und Erschießen sind die am meisten angewandten Suizidarten. Vergleicht man Zeitraum I mit II, so fällt die signifikante Zunahme von Todesfällen im Zusammenhang mit ärztlichen Maßnahmen auf. Eine signifikante Abnahme von Suizidenten ist durch die abnehmende Obduktionsrate in dieser Gruppe zu begründen. Die relative und absolute Fallzahl an Tötungsdelikten im Obduktionsgut weisen keine wesentliche Veränderung auf. Diskussion/Schlussfolgerung: Die Ergebnisse dieser Studie stimmen großteils mit der Literatur überein. Im Zeitvergleich zeigt sich eine relative Zunahme nichtnatürlicher Todesfälle im gerontologischen Obduktionsgut. Dies wird durch den Anstieg von Obduktionen nach iatrogenen Komplikationen wesentlich mitgeprägt.
Background: Tuberous sclerosis complex (TSC), a multisystem genetic disorder, affects many organs and systems, characterized by benign growths. This German multicenter study estimated the disease-specific costs and cost-driving factors associated with various organ manifestations in TSC patients. Methods: A validated, three-month, retrospective questionnaire was administered to assess the sociodemographic and clinical characteristics, organ manifestations, direct, indirect, out-of-pocket, and nursing care-level costs, completed by caregivers of patients with TSC throughout Germany. Results: The caregivers of 184 patients (mean age 9.8 ± 5.3 years, range 0.7–21.8 years) submitted questionnaires. The reported TSC disease manifestations included epilepsy (92%), skin disorders (86%), structural brain disorders (83%), heart and circulatory system disorders (67%), kidney and urinary tract disorders (53%), and psychiatric disorders (51%). Genetic variations in TSC2 were reported in 46% of patients, whereas 14% were reported in TSC1. Mean total direct health care costs were EUR 4949 [95% confidence interval (95% CI) EUR 4088–5863, median EUR 2062] per patient over three months. Medication costs represented the largest direct cost category (54% of total direct costs, mean EUR 2658), with mechanistic target of rapamycin (mTOR) inhibitors representing the largest share (47%, EUR 2309). The cost of anti-seizure drugs (ASDs) accounted for a mean of only EUR 260 (5%). Inpatient costs (21%, EUR 1027) and ancillary therapy costs (8%, EUR 407) were also important direct cost components. The mean nursing care-level costs were EUR 1163 (95% CI EUR 1027–1314, median EUR 1635) over three months. Total indirect costs totaled a mean of EUR 2813 (95% CI EUR 2221–3394, median EUR 215) for mothers and EUR 372 (95% CI EUR 193–586, median EUR 0) for fathers. Multiple regression analyses revealed polytherapy with two or more ASDs and the use of mTOR inhibitors as independent cost-driving factors of total direct costs. Disability and psychiatric disease were independent cost-driving factors for total indirect costs as well as for nursing care-level costs. Conclusions: This study revealed substantial direct (including medication), nursing care-level, and indirect costs associated with TSC over three months, highlighting the spectrum of organ manifestations and their treatment needs in the German healthcare setting.
Objectives: The aim of this study was to investigate the relationship between anamnestic, axiographic and occlusal parameters and postural control in healthy women aged between 41 and 50 years. Materials and methods: A total of 100 female participants aged between 41 and 50 (45.12 ± 2.96) years participated in the study. In addition to completing a general anamnesis questionnaire, lower jaw movements were measured axiographically, dental occlusion parameters were determined using a model analysis and postural parameters were recorded using a pressure measurement platform. The significance level was 5%. Results: An increasing weight and a rising BMI lead to a weight shifted from the rearfoot (p ≤ 0.01/0.04) to the forefoot (p ≤ 0.01/0.02). A limited laterotrusion on the right resulted in a lower forefoot load and an increased rearfoot load (p ≤ 0.01). Laterotrusion to the left (extended above the standard) showed a lower frontal sway (p ≤ 0.02) and a reduced elliptical area, height and width (p ≤ 0.01, 0.02, 0.03). Thus, the extent of deviation correlated with reduced right forefoot loading (p ≤ 0.03) and the extent of deflection correlated with increased left foot loading (p ≤ 0.01). The higher the extent of angle class II malocclusion, the larger the ellipse area (p ≤ 0.04) and the ellipse height (p ≤ 0.02) resulted. Conclusions: There is a connection between weight, BMI and laterotrusion, as well as between angle class II malocclusion and postural control in women aged between 41 and 50 years. Interdisciplinary functional examinations of mandibular movements treating possible limitations can be conducive for an improvement of postural control. Clinical relevance: Angle class II malocclusion has a negative influence on postural control.
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.